Cytovale, a leading biotech company based in San Francisco, is dedicated to revolutionizing patient care through innovative early detection technologies. Their FDA-cleared rapid sepsis diagnostic, IntelliSep®, is transforming the way Emergency Departments assess immune activation to expedite the transition to life-saving therapies. Backed by Norwest Venture Partners, Sands Capital, and Global Health Investment Corporation, Cytovale’s cutting-edge approach is reshaping the landscape of healthcare. A recent multicenter study unveiled the significant impact of IntelliSep® on patient outcomes, showcasing a 56% increase in safe ED discharges for low-risk patients without a rise in 30-day return visits. By streamlining sepsis testing at triage, hospitals can optimize inpatient bed utilization and enhance overall care quality. This groundbreaking research, presented at the 2025 Association for Diagnostics & Laboratory Medicine Clinical Lab Expo, highlights the pivotal role of early sepsis detection in improving triage efficiency and patient safety. Visit Cytovale’s website and join their journey towards transforming emergency care.
Read more from finance.yahoo.com